Digital Repository

Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy

Show simple item record

dc.contributor.author Poddar, N.K.
dc.contributor.author Agrawal, D.
dc.contributor.author Agrawal, Y.
dc.contributor.author Wijayasinghe, Y.S.
dc.contributor.author Mukherjee, A.
dc.contributor.author Khan, S.
dc.date.accessioned 2022-09-06T06:50:03Z
dc.date.available 2022-09-06T06:50:03Z
dc.date.issued 2022
dc.identifier.citation Biochimica et Biophysica Acta. Molecular Basis of Disease. 2022;1868(11):166524 [Epub 2022 Aug 17] en_US
dc.identifier.issn 0925-4439
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/25156
dc.description Indexed in MEDLINE. en_US
dc.description.abstract Alzheimer's disease (AD) and prostate cancer (PCa) are considered the leading causes of death in elderly people worldwide. Although both these diseases have striking differences in their pathologies, a few underlying mechanisms are similar when cell survival is considered. In the current study, we employed an in-silico approach to decipher the possible role of bacterial proteins in the initiation and progression of AD and PCa. We further analyzed the molecular connections between these two life-threatening diseases. The androgen deprivation therapy used against PCa has been shown to promote castrate resistant PCa as well as AD. In addition, cell signaling pathways, such as Akt, IGF, and Wnt contribute to the progression of both AD and PCa. Besides, various proteins and genes are also common in disease progression. One such similarity is mTOR signaling. mTOR is the common downstream target for many signaling pathways and plays a vital role in both PCa and AD. Targeting mTOR can be a favorable line of treatment for both AD and PCa. However, drug resistance is one of the challenges in effective drug therapy. A few drugs that target mTOR have now become ineffective due to the development of resistance. In that regard, phytochemicals can be a rich source of novel drug candidates as they can act via multiple mechanisms. This review also presents mTOR targeting phytochemicals with promising anti-PCa, anti-AD activities, and approaches to overcome the issues associated with phytochemical-based therapies in clinical trials. en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.subject Alzheimer's disease en_US
dc.subject In-silico en_US
dc.subject Nano-drug delivery en_US
dc.subject Phytochemicals en_US
dc.title Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account